[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100648754":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":16,"locations":25,"responsibleParty":71,"collaborators":10,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":75,"sex":81,"minAge":82,"maxAge":10,"enrollmentInfo":83,"targetDuration":10,"studyType":86,"phases":10,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":96,"whyStopped":10,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"IRCCS Azienda Ospedaliero-Universitaria di Bologna","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Patients with complicated urinary tract infections with bacteremia caused by resistant bacteria",null,"Patients treated with cefepime\u002Fenmetazobactam (FEP\u002FMETA), a drug recently introduced into clinical practice in Italy, compared with the best available therapy (BAT) for targeted treatment of complicated urinary tract infections with bacteremia caused by microorganisms harboring specific antibiotic resistance mechanisms (extended-spectrum beta-lactamase producers and OXA-48-type carbapenemase producers).",[13],{"name":14,"affiliation":5,"role":15},"Cecilia Maria Bonazzetti, MD","PRINCIPAL_INVESTIGATOR",[17,21],{"name":14,"role":18,"phone":19,"phoneExt":10,"email":20},"CONTACT","+390512143595","cecilia.bonazzetti@unibo.it",{"name":22,"role":18,"phone":23,"phoneExt":10,"email":24},"Maddalena Giannella, MD, PhD","+390512143199","maddalena.giannella@unibo.it",[26,41,56],{"facility":5,"status":10,"city":27,"state":28,"zip":29,"country":28,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"Bologna","Italy","40138","IT",{"type":32,"coordinates":33},"Point",[34,35],11.33875,44.49381,{"lat":35,"lon":34},[38,40],{"name":14,"role":18,"phone":39,"phoneExt":10,"email":20},"+39 051 214 3595",{"name":14,"role":15,"phone":10,"phoneExt":10,"email":10},{"facility":42,"status":10,"city":43,"state":28,"zip":44,"country":28,"countryCode":30,"cosmosGeoPoint":45,"geoPoint":49,"contacts":50},"Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione (ARNAS) Garibaldi","Catania","95122",{"type":32,"coordinates":46},[47,48],15.07041,37.49223,{"lat":48,"lon":47},[51,55],{"name":52,"role":18,"phone":53,"phoneExt":10,"email":54},"Federica Cosentino, MD","+39 0957594936","fcosentino@arnasgaribaldi.it",{"name":52,"role":15,"phone":10,"phoneExt":10,"email":10},{"facility":57,"status":10,"city":58,"state":28,"zip":59,"country":28,"countryCode":30,"cosmosGeoPoint":60,"geoPoint":64,"contacts":65},"ASST Fatebenefratelli Sacco","Milan","20157",{"type":32,"coordinates":61},[62,63],12.59836,42.78235,{"lat":63,"lon":62},[66,70],{"name":67,"role":18,"phone":68,"phoneExt":10,"email":69},"Matteo Passerini, MD","+39 02 6363 4967","passerini.matteo@asst-fbf-sacco.it",{"name":67,"role":15,"phone":10,"phoneExt":10,"email":10},{"type":72,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100648754","cefepimeenmetazobactam-for-bacteremic-complicated-urinary-tract-infections-100648754",false,"NCT07725848","Cefepime\u002FEnmetazobactam for Bacteremic Complicated Urinary Tract Infections","Cefepime\u002FEnmetazobactam for Bacteremic Complicated Urinary Tract Infections: an Observational Prospective Study","CP-CUTI","Inclusion Criteria:\n\n* Patients with bacteremic cUTIs caused by Gram-negative bacteria treated with FEP\u002FMETA or BAT\n* Adult population (age ≥ 18 years)\n* Signed informed consent form\n\nExclusion Criteria:\n\n* Polymicrobial\u002Fmixed infections (Gram-positive bacteria or fungi together with Gram-negative microorganisms), except in cases involving multiple Gram-negative bacteria susceptible to the study drugs\n* Patients with negative blood cultures\n* Isolation of Gram-negative microorganisms not susceptible to the study drugs (e.g., KPC-producing organisms)\n* Patients in palliative care or with a high likelihood of death within 72 hours from the index positive blood culture\n* Patients treated with inappropriate therapy for more than 48 hours\n* Patients discharged early without follow-up blood cultures\n* History of significant hypersensitivity or allergic reactions to cefepime, to any of the excipients in the respective formulations, or to beta-lactamase inhibitors (e.g., tazobactam)","ALL","18 Years",{"count":84,"type":85},200,"ESTIMATED","OBSERVATIONAL","This study is designed to better understand how well a new antibiotic combination, cefepime\u002Fenmetazobactam (FEP\u002FMETA), works in patients with complicated urinary tract infections that have spread to the bloodstream (bacteremia). These infections are caused by bacteria that are resistant to several commonly used antibiotics, including bacteria that produce extended-spectrum beta-lactamases (ESBLs) or OXA-48 carbapenemases.\n\nThe main goal of the study is to compare cefepime\u002Fenmetazobactam with the best currently available antibiotic treatments to see how quickly blood cultures become negative after treatment begins, which is an important sign that the infection is improving.",[89,90],"Complicated Urinary Tract Infections","Antibiotic Resistance",[89,92,93,90,94,95],"Cefepime\u002FEnmetazobactam (FEP\u002FMETA)","Bacteremia","Beta-lactamase Producers","OXA-48-type Carbapenemase Producers","NOT_YET_RECRUITING","2026-07-22",{"date":99,"type":100},"2026-07-24","ACTUAL",{"date":102,"type":85},"2026-10-15",{"date":104,"type":85},"2029-10-15",{"name":5,"class":6},3]